# First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001

> **NCT02110420** · PHASE1 · COMPLETED · sponsor: **Celgene Corporation** · enrollment: 96 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** CC-90001
- **DRUG:** CC-90001
- **DRUG:** CC-90001
- **DRUG:** CC-90001
- **DRUG:** CC-90001
- **DRUG:** CC-90001
- **DRUG:** CC-90001
- **DRUG:** CC-90001
- **DRUG:** CC-90001
- **DRUG:** CC-90001
- **DRUG:** Placebo
- **DRUG:** CC-90001
- **DRUG:** CC-90001
- **DRUG:** CC-90001

## Key facts

- **NCT ID:** NCT02110420
- **Lead sponsor:** Celgene Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2014-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02110420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02110420, "First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02110420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*